Shenzhen - Delayed Quote CNY

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)

16.52
+1.74
+(11.77%)
At close: May 23 at 3:04:19 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
293,046.57
324,815.96
364,175.43
548,988.62
584,291.44
Cost of Revenue
60,570.05
62,271.66
64,707.91
101,444.84
111,628.06
Gross Profit
232,476.52
262,544.31
299,467.52
447,543.78
472,663.38
Operating Expense
267,362.01
296,684.55
657,010.31
670,548.79
704,006.43
Operating Income
-34,885.50
-34,140.25
-357,542.78
-223,005.01
-231,343.05
Net Non Operating Interest Income Expense
-545.47
-220.96
1,308.49
1,344.62
750.44
Pretax Income
-34,953.93
-34,316.22
-366,447.90
-243,070.73
-212,958.08
Tax Provision
--
113,415.07
32,444.90
-46,062.64
-75,557.89
Net Income Common Stockholders
-143,408.20
-144,842.56
-398,892.80
-197,008.09
-137,400.20
Basic EPS
-0.29
--
-0.84
-0.41
-0.29
Diluted EPS
-0.29
--
-0.84
-0.41
-0.29
Basic Average Shares
482,808.53
--
474,872.38
480,507.53
473,793.78
Diluted Average Shares
482,808.53
--
474,872.38
480,507.53
473,793.78
Total Operating Income as Reported
-34,734.28
-33,614.42
-366,155.03
-242,973.37
-213,213.28
Total Expenses
327,932.07
358,956.21
721,718.21
771,993.63
815,634.49
Net Income from Continuing & Discontinued Operation
-143,408.20
-144,842.56
-398,892.80
-197,008.09
-137,400.20
Normalized Income
-143,710.16
-145,119.93
-391,453.48
-175,270.90
-135,320.48
Interest Income
347.31
491.94
2,653.89
1,818.27
1,591.71
Interest Expense
822.33
644.93
1,167.37
357.89
651.19
Net Interest Income
-545.47
-220.96
1,308.49
1,344.62
750.44
EBIT
-34,131.60
-33,671.29
-365,280.53
-242,712.84
-212,306.89
EBITDA
-34,131.60
-10,896.25
-332,968.29
-208,721.49
-175,507.10
Reconciled Cost of Revenue
60,570.05
62,271.66
64,707.91
101,444.84
111,628.06
Reconciled Depreciation
30,360.01
22,775.04
32,312.25
33,991.35
36,799.79
Net Income from Continuing Operation Net Minority Interest
-143,408.20
-144,842.56
-398,892.80
-197,008.09
-137,400.20
Total Unusual Items Excluding Goodwill
301.96
369.83
-9,919.09
-26,819.58
-3,223.38
Total Unusual Items
301.96
369.83
-9,919.09
-26,819.58
-3,223.38
Normalized EBITDA
-34,433.56
-11,266.08
-323,049.20
-181,901.91
-172,283.72
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
92.46
-2,479.77
-5,082.39
-1,143.66
12/31/2021 - 4/15/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

688336.SS Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
54.67
-3.56%
 
301301.SZ Yili Chuanning Biotechnology Co.,Ltd.
13.12
+2.02%
 
IFRX InflaRx N.V.
1.8500
+1.65%
 
KRON Kronos Bio, Inc.
0.6887
+0.10%
 
1530.HK 3SBIO
20.050
+0.35%
 
HOPHF Hemogenyx Pharmaceuticals Plc
0.0400
0.00%
 
TRSBF 3SBio Inc.
3.0000
0.00%
 
2269.HK WuXi Biologics (Cayman) Inc.
23.850
-0.83%
 
CLDX Celldex Therapeutics, Inc.
20.35
-0.10%
 
MDGL Madrigal Pharmaceuticals, Inc.
267.56
-2.12%